Ratings Acrobiosystems Co.,Ltd.

Equities

301080

CNE100004S13

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
40.98 ^CNY	+1.51%		-5.09%	-30.47%

Apr. 24	Acrobiosystems Co.,Ltd. Proposes Final Cash Dividend for 2023	CI
Apr. 18	Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The firm trades with high earnings multiples: 28.16 times its 2024 earnings per share.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ACROBIOSYSTEMS CO.,LTD.	-30.47%	669M	-
ELI LILLY AND COMPANY	+32.09%	694B	C+
NOVO NORDISK A/S	+29.39%	593B	B
JOHNSON & JOHNSON	-1.34%	371B	C+
MERCK & CO., INC.	+20.34%	331B	B-
ABBVIE INC.	+7.39%	290B	C+
ASTRAZENECA PLC	+14.25%	239B	B+
ROCHE HOLDING AG	-3.03%	209B	A+
NOVARTIS AG	+10.02%	209B	B-
AMGEN INC.	+8.49%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes